08:00 | Registration | |||
09:15 | Welcome Address- Dr Sanjay Bajaj, Managing Director, Select Biosciences India | |||
09:30 |
| |||
09:40 | Introduction of Resource Persons and Memento Presentation | |||
10:00 | Business Networking Session | |||
10:10 | Group Photograph | |||
10:25 | Coffee Break and Networking in Exhibition Area | |||
Session I- NGS in Genetic Disorders and Reproductive Medicine | ||||
10:55 | Next Generation Sequencing for Clinical Diagnostics: Five year Experience of an Academic Laboratory The speaker will describe how they created and implemented a single broad-based NGS sequencing assay to meet the genetic testing needs at their organization. Further, the talk will discuss about the feasibility of this broad-based NGS platform by aggregating a sufficient sample volume from many individually rare tests and providing a flexible ordering for custom, patient-specific panels. | |||
11:25 | Q/A Discussion | |||
11:30 | Next Generation Genome Diagnosis for the Multi-Disciplinary Management of Inherited Cardiovascular Conditions In this talk, the speaker presents their experience of managing inherited cardiomyopathies in a busy tertiary hospital heart failure clinic, as the role model for NGS diagnosis in ICC multi-disciplinary care. | |||
12:00 | Q/A Discussion | |||
12:05 | Recurrent Pregnancy Loss- Solving the Biggest Diagnostic Dilemma by Advanced Clinical Genomic Approaches | |||
12:35 | Q/A Discussion | |||
12:40 | Next-Generation Sequencing for Noninvasive Prenatal Testing | |||
13:10 | Q/A Discussion | |||
13:15 | Interactive Session | |||
13:45 | Lunch and Networking in Exhibition Area | |||
Session II- Integrating Next Generation Sequencing into Clinical Oncology | ||||
14:45 | Implementation of NGS for Clinical Cancer Diagnostics | |||
15:15 | Q/A Discussion | |||
15:20 | Deep Sequencing identifies Novel Rectal Cancer Genes The talk will highlight how comprehensive characterization of early onset sporadic rectal cancer (EOSRC) by whole exome sequencing which detects absence of Wnt or MSI along with identification of known and novel mutational events. The study revealed several unique genetic aberrations that drive EOSRC, a CRC subtype unique to the Indian population. | |||
15:50 | Q/A Discussion | |||
15:55 | A New Perspective in Precision Oncology: Making a Case for Integrated Approaches In this talk, the speaker intends to present some of his data and perspective on the need for an integrated approach for a more promising precision oncology where a combinatorial analysis should be performed on the mutations (classical approach: individually), haplotypes and a holistic network analysis stemming from meta analysis of transcriptomic data. | |||
16:25 | Q/A Discussion | |||
16:30 | Role of Clinical Genomics and Liquid Biopsy in Personalized Medicine The speaker will present data and clinical case studies to establish the utility of different molecular diagnostic platforms (including multigene testing by NGS and Liquid Biopsy) in both early diagnosed and advanced cancer cases and implication of stratifying patients based on their molecular profile that could potentially benefit/not benefit from targeted therapy and chemo-radiation. | |||
17:00 | Q/A Discussion | |||
17:05 | Open Discussion and Coffee | |||
17:30 | End of First Day of the Conference |
Session III- NGS in Transplant and Chronic Diseases | ||
09:15 | Novel HLA Typing Technology: Full Length Super-Resolution HLA Typing The talk will discuss how Full Length Super-Resolution HLA typing decodes HLA alleles from any individuals and populations and how Full length HLA allelic information may act as “personalized predictive health record” for an individual and save many lives. | |
09:45 | Q/A Discussion | |
09:50 | NGS based Comprehensive Screening in Monogenic Forms of Diabetes in India - Understanding the Diversity The speaker will describe how they established and utilized a cost-effective multiplex PCR coupled NGS based approach to screen MODY genes in parallel & identify a wide spectrum of mutations in MODY along with PDX1 and NEUROD1 digenic mutations. | |
10:20 | Q/A Discussion | |
10:25 | Using NGS in Clinic- Clinician Perspective The speaker has developed their own NGS panels for few renal diseases (Manuscripts submitted for publication) and could discuss the utility as well as challenges and barriers to its application in a clinical setting | |
10:55 | Q/A Discussion | |
11:00 | Coffee Break and Networking in Exhibition Area | |
Session IV- NGS in Neuro and Ocular Genetics | ||
11:30 | NGS (Next Generation sequencing ) in NGS (Neuro- Genetic syndromes) - Clinical Experience from a Tertiary Care Centre | |
12:00 | Q/A Discussion | |
12:05 | Identification of New Candidate Genes for Ocular Disorders The Presenter will discuss in detail about their experience in the field of ophthalmic genetics related to new candidate genes identified for Congenital Hereditary Endothelial Dystrophy (CHED), Pseudoexfoliation syndrome (PXF) and Primary Angle Closure Glaucoma (PACG). | |
12:35 | Q/A Discussion | |
12:40 | Role of Microglial mediated Inflammation in Retinopathy of Prematurity Based on comprehensive genomics and proteomics, the present will discuss how their study provided a proof of concept that tear MMP levels could serve as a potential predictor for Retinopathy of prematurity (ROP) progression in preterm babies. | |
13:10 | Q/A Discussion | |
13:15 | Interactive Session | |
13:45 | Lunch and Networking in Exhibition Area | |
Session V- NGS and Bioinformatics Data Processing for Cancer and Infectious Diseases | ||
14:45 | Data Quality and Interpretation: Do’s and Don’ts In this talk, the orator will discuss strategies for evaluating and optimising multi-step bioinformatics pipelines and will highlight how the sequencing data helps identifying common problems such as accessioning errors, cross-contamination, instrument performance degradation, NGS protocol errors etc. Finally, efficient strategies for second method evaluation that can be used to confirm these variants will be suggested. | |
15:15 | Q/A Discussion | |
15:20 | A Clinically Applicable Mutational Burden Threshold is a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors | |
15:50 | Q/A Discussion | |
15:55 | Modeling Bacterial Chromosome Organization using Hi-C Data The speaker will discuss about developing method using Chromosome conformation capture techniques (often abbreviated to 3C technologies or Hi-C or 3C) to obtain the 3-D organization of a genome and apply it to the C. crescentus genome. | |
16:25 | Q/A Discussion | |
16:30 | Impact of Alternate Data Processing Methods on Gut Microbiome | |
17:00 | Q/A Discussion | |
17:05 | Closing Remarks | |
17:15 | Farewell Coffee |